Data from the REWIND trial suggest that dulaglutide has cardioprotective properties. 

The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c. 

Care of the elderly can be very challenging. Can adding yet another medication actually help?   

Is the risk as substantial as was initially reported?

The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss. 

Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene? 

In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure. 

CoviDIAB Registry will explore why COVID-19 can increase complications in people with pre-existing diabetes, and may also be driving new cases. 

If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.

Explore three methods to prevent future acute myocardial infarction with diabetes as an underlying agent.